Choledochal cysts are characterized by single or multiple cystic dilatations of the intrahepatic and / or extrahepatic biliary ducts. The typical presentation of this condition is non-specific. Clinicians must have a high clinical suspicion of choledochal cysts while investigating patients with jaundice, abdominal pain, and abdominal mass. There are multiple classifications for choledochal cysts . The Todani classification system is the most widely used in clinical practice. Based on clinical practice and thinking, we established a new “three regions and five types” classification system on the basis of Todani classification to guide clinical work, but further verification is needed. Surgery is the mainstay of treatment for choledochal cysts and the approach depends on the cyst type and the extent of hepatobiliary pathology. The principles of treatment include complete excision of the cyst and restoration of biliary-intestinal continuity. In view of the risk of biliary malignancy continues to be high after surgery, long-term follow-up is strongly recommended.
ObjectivesTo systematically review the association between the variants of HNF1B gene and the risk of prostate cancer.MethodsPubMed, EMbase, The Cochrane Library, CNKI, CBM and WanFang Data databases were electronically searched to collect case-control studies on the association between the variants of HNF1B gene and risk of prostate cancer from inception to December, 2017. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Meta-analysis was then performed using Stata 14.0 software.ResultsA total of 15 case-control studies involving 30 532 patients and 38 832 controls were included. The results of meta-analysis showed that: there was a strong significant association between rs4430796 variants (Gvs.A: OR=0.802, 95%CI 0.784 to 0.821, P<0.001; GGvs.AA: OR=0.659, 95%CI 0.606 to 0.717, P<0.001; AGvs.AA: OR=0.762, 95%CI 0.714 to 0.814, P<0.001), rs11649743 variants (Avs.G: OR=0.875, 95%CI 0.820 to 0.941, P<0.001; AAvs.GG: OR=0.669, 95%CI 0.564 to 0.792, P<0.001; AGvs.GG: OR=0.855, 95%CI 0.798 to 0.916, P<0.001), rs7501939 variants (Avs.G: OR=0.833, 95%CI 0.807 to 0.859, P<0.001), rs3760511 variants (Avs.C: OR=0.834, 95%CI 0.803 to 0.868, P<0.001) and risk of prostate cancer.ConclusionsCurrent evidence shows that HNF1B gene variants are associated with risk of prostate cancer. Due to limited quantity and quality of the included studies, more high quality studies are required to verify the above conclusion.
Surgery is the only effective treatment for congenital choledochal cysts, as it allows for the resection of the cysts, the complete relief of cholangitis, and the prevention of canceration of cysts. The key elements of surgery for central choledochal cysts involve the cysts resection, bile-intestinal anastomosis, and biliopancreatic diversion. The difficulty in operating on central choledochal cysts lies in the rational decision making and effective management of cysts in the hilar and pancreatic regions. Depending on the type of central choledochal cysts with different anatomical patterns, a reasonable and feasible individualized surgical management strategy can be established to effectively avoid adverse therapeutic consequences such as postoperative biliary leakage, cholangio-intestinal anastomotic stricture, residual choledochal cysts and its carcinogenesis.
A complex mechanism of reduced number of bile duct innervating ganglion cells, smooth muscle distribution, foregut duplications, and abnormal pancreaticobiliary duct junction, which occurs during embryonic development and after birth in a genetic context, can lead to pathological congenital biliary dilatation. As a precancerous lesion of the biliary system, irrational treatment of congenital biliary dilatation will further increase the risk of malignancy in patients. By understanding the causes, pathological features, and limitations of early detection techniques of malignant tumor secondary to congenital biliary dilatation is helpful to clarify the key points in the management of congenital biliary dilatation, reduce the incidence of postoperative adverse treatment events and avoid the medical risk of secondary malignancy.
Objective To investigate the relation between artery location for anastomosis and recipient’s hepatic arterial anatomic variation or pathological abnormity in adult liver transplantation. Methods From March 2004 to July 2006, 80 cases of adult orthotopic liver transplantation (OLT) were performed in this hospital. Preoperative magnetic resonance angiography combined with operative artery dissection were performed to recognize and classify the hepatic arterial variation or pathological abnormity, then the arterial anastomotic location and stoma diameter were recorded. The location and diameter of anastomosis were compared between variation group and non-variation group. Results The recipient’s hepatic arterial variation rate was 11.3%(9/80), 8/9 of variable artery were right hepatic arteries which arose from gastroduodenal artery (GDA), common hepatic artery (CHA), celiac artery or superior mesenteric artery. The locations for anastomosis were the branch patches of CHA (7/9) and GDA (2/9). The pathological abnormities comprised of hepatic arterial intimal dissection (1 case) and hepatic arterial stenosis (1 case), the corresponding anastomotic location was the end of CHA in former case and anterior wall of suprarenal aorta in latter case. The proportion of anastomotic locations differed statistically between variation group and non-variation group (χ2=18.679, P＜0.01). The anastomotic diameter of CHA branch patch in variation group had no statistic difference compared with branch patch of CHA or proper hepatic artery (PHA) in non-variation group (Pgt;0.05). Conclusion The recipient’s hepatic arterial variation influences the selection of locations for anastomosis, the branch patch of CHA is the preferred location. The anastomotic stoma diameter of PHA branch patch in non-variation group obtains a similar size of CHA branch patch in variation group, the PHA branch patch can be used as a common location when arterial variations are absent.
ObjectiveTo investigate the prognostic impact of tumor location in gallbladder carcinoma in different sites and evaluate the effect of surgical operation on the median survival time of patients.MethodsFrom 2012 to 2016, 382 patients with gallbladder cancer in the Eastern Hepatobiliary Surgery Hospital were divided into 163 cases of gallbladder duct cancer and 219 cases of gallbladder bottom and body cancer. They were received radical resection, extended radical resection and palliative resection.ResultsThe mean survival time was (19.57+15.63) months in the bottom and body cancer group, (14.62+11.12) months in the cystic duct carcinoma group, and the survival time was significantly different between the two groups (P<0.05). After radical surgery, the mean survival time in the cystic duct carcinoma group and the bottom and body cancer group were (23.82±12.47) months and (30.63±17.81) months, respectively, there was no significant difference between the two groups (P>0.05). The multivariate analysis indicated that tumor location, surgical radical therapy, clinical stage, pathological grade, and pathological classification were all independent risk factors influencing the prognosis of patients (P<0.05). There was no significant difference in median survival time between the two groups (P>0.05).ConclusionsThe prognosis of patients with cystic duct gallbladder carcinoma is worse than that of patients with the bottom and body cancer of the gallbladder, but the prognosis of the two groups after radical resection is similar. The prognosis of patients with extended radical operation according to the condition is similar to that of routine radical operation. There are some differences in clinical stage, pathological grade and pathological classification between the two groups of gallbladder cancer patients. In addition, the great differences exist in the surgical methods, especially in extended radical operation. Therefore, the treatment of gallbladder cancer in these two locations should be treated differently.